Plasma myeloperoxidase level and peripheral arterial disease

European Journal of Clinical Investigation, 05/02/2012

The authors suggest consideration of plasma Myeloperoxidase (MPO) for risk stratification of major adverse cardiovascular events in patients with peripheral arterial disease. In contrast, MPO–463G>A is not an independent risk factor for major adverse cardiovascular events in patients suffering from peripheral arterial disease.

Print Article Summary Cat 2 CME Report